Overview

Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
Niacin will improve postprandial hyperlipidaemia and cardiovascular risks indices via its lipid lowering as well as via pleiotropic effects in patients with polycystic ovary syndrome (PCOS).
Phase:
Phase 4
Details
Lead Sponsor:
Hull and East Yorkshire Hospitals NHS Trust
Hull University Teaching Hospitals NHS Trust
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Niacin
Niacinamide
Nicotinic Acids